Most Read News

Revenue from operations was at ₹767.5 crore, 12.7% higher than ₹681 crore reported in the March quarter of FY24

The company has a strong foothold in the Indian pharma market as well as in the international market where it sells its products in more than 55 countries

The Board of Directors have recommended a final dividend of ₹35 per equity share, i.e., 350% for the financial year FY25

Revenue from operations in the quarter was at ₹534 crore, a 13% increase from ₹471 crore in Q4 FY24

Annual income at the company also grew by a big margin of ₹31,724 crore in FY25 from ₹29,002 crore in FY24, up 9.4% on yearly basis

Revenue from operations was down by 20.3% y-o-y to ₹1,360.9 crore in Q4 FY25 from ₹1,708.2 crore in Q4 FY24

An EBITDA of ₹498 crore at Q4 FY25 shrank by 6.4% over ₹532.2 crore in the corresponding quarter last year.

Domestic patient volumes rose over 15% year-on-year in the March quarter, helping to offset a sharp 53% decline in medical tourism from Bangladesh

Revenue increased 11% YoY to ₹265.30 crore from ₹240 crore in Q4 FY24, suggesting healthy sales traction.

The hospital chain’s EBITDA for the March 2025 quarter jumped 22.7 YoY% to ₹57.2 crore against ₹46.6 crore in Q4 FY24